UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

Cytokinins Reduce Viral Replication and Alter Plaque Morphology of Frog Virus 3 In Vitro

Viruses, 2024-06, Vol.16 (6), p.826

2024

Volltextzugriff (PDF)

Components of the Nucleotide Salvage Pathway Increase Frog Virus 3 (FV3) Replication

Viruses, 2023-08, Vol.15 (8), p.1716

2023

Volltextzugriff (PDF)

The soybean (Glycine max L.) cytokinin oxidase/dehydrogenase multigene family; Identification of natural variations for altered cytokinin content and seed yield

Plant direct, 2021-02, Vol.5 (2), p.e00308-n/a

2021

Volltextzugriff (PDF)

Profiling of adenine‐derived signaling molecules, cytokinins, in myotubes reveals fluctuations in response to lipopolysaccharide‐induced cell stress

Physiological reports, 2023-12, Vol.11 (23), p.e15870-n/a

2023

Volltextzugriff (PDF)

Canis familiaris tissues are characterized by different profiles of cytokinins typical of the tRNA degradation pathway

The FASEB journal, 2018-12, Vol.32 (12), p.6575-6581

2018

Volltextzugriff (PDF)

Phytohormone metabolism in human cells: Cytokinins are taken up and interconverted in HeLa cell culture

FASEB bioAdvances, 2019-05, Vol.1 (5), p.320-331

2019

Volltextzugriff (PDF)

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19

The New England journal of medicine, 2022-06, Vol.386 (23), p.2188-2200

2022

Volltextzugriff (PDF)

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19

The New England journal of medicine, 2022-06, Vol.386 (23), p.2188-2200

2022

Volltextzugriff (PDF)

AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019

Clinical infectious diseases, 2023-04, Vol.76 (7), p.1247-1256

2023

Volltextzugriff (PDF)

Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials

Infectious diseases and therapy, 2024-06, Vol.13 (6), p.1253-1268

2024

Volltextzugriff (PDF)

Barriers to Psychologists Seeking Mental Health Care

Professional psychology, research and practice, 2013-06, Vol.44 (3), p.150-157

2013

Volltextzugriff (PDF)

Dissolution Challenges Associated with the Surface pH of Drug Particles: Integration into Mechanistic Oral Absorption Modeling

The AAPS journal, 2022-01, Vol.24 (1), p.17-17, Article 17

2022

Volltextzugriff (PDF)

Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults

The Journal of infectious diseases, 2023-05, Vol.227 (10), p.1153-1163

2023

Volltextzugriff (PDF)

Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial

Infectious diseases and therapy, 2024-03, Vol.13 (3), p.521-533

2024

Volltextzugriff (PDF)

Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial

Infectious diseases and therapy, 2023-09, Vol.12 (9), p.2269-2287

2023

Volltextzugriff (PDF)

Serum AZD7442 (tixagevimab–cilgavimab) concentrations and in vitro IC50 values predict SARS‐CoV‐2 neutralising antibody titres

Clinical & translational immunology, 2024, Vol.13 (6), p.n/a

2024

Volltextzugriff (PDF)

Intramuscular AZD7442

The New England journal of medicine, 2022-06, Vol.386 (23), p.2188

2022

Volltextzugriff (PDF)

529. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Phase 3 Study

Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)

2023

Volltextzugriff (PDF)

1354. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of COVID-19: 15-Month Final Analysis of the PROVENT Phase 3 Study

Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)

2023

Volltextzugriff (PDF)

1353. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of COVID-19: Final Analysis of the STORM CHASER Phase 3 Study

Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)

2023

Volltextzugriff (PDF)

LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults

Open forum infectious diseases, 2021-12, Vol.8 (Supplement_1), p.S810-S810

2021

Volltextzugriff (PDF)

Assessing multimodal emotion recognition in multiple sclerosis with a clinically accessible measure

Multiple sclerosis and related disorders, 2024-06, Vol.86, p.105603-105603, Article 105603

2024

Volltextzugriff (PDF)

Serum AZD7442 (tixagevimab–cilgavimab) concentrations and in vitro IC 50 values predict SARS‐CoV‐2 neutralising antibody titres

Clinical & translational immunology, 2024-01, Vol.13 (6)

2024

Volltextzugriff (PDF)

Serum AZD7442 (tixagevimab-cilgavimab) concentrations and in vitroIC50 values predict SARS-CoV-2 neutralising antibody titres

Clinical & translational immunology, 2024-01, Vol.13 (6), p.e1517

2024

Volltextzugriff (PDF)

1924. Outpatient Treatment With the SARS-CoV-2–Neutralizing Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) for Preventing COVID-19 Hospitalizations in the Phase 3 TACKLE Trial

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(29)
Buchkapitel
(1)

Sprache

Englisch
(30)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(16)
Science & Technology
(16)
Monoclonal Antibodies
(8)
Covid-19
(6)
Humans
(6)
Infectious Diseases
(6)
Adult
(5)
Coronaviruses
(5)
Pharmacokinetics
(5)
Sars-Cov-2
(5)
Biosynthesis
(4)
Cytokinins
(4)
Infections
(4)
Original Research
(4)
Psychology
(4)
Safety
(4)
Severe Acute Respiratory Syndrome Coronavirus 2
(4)
Social Sciences
(4)
Antibodies
(3)
Azd7442
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Cytokinins Reduce Viral Replication and Alter Plaque Morphology of Frog Virus 3 In Vitro

Components of the Nucleotide Salvage Pathway Increase Frog Virus 3 (FV3) Replication

The soybean (Glycine max L.) cytokinin oxidase/dehydrogenase multigene family; Identification of natural variations for altered cytokinin content and seed yield

Profiling of adenine‐derived signaling molecules, cytokinins, in myotubes reveals fluctuations in response to lipopolysaccharide‐induced cell stress

Canis familiaris tissues are characterized by different profiles of cytokinins typical of the tRNA degradation pathway

Phytohormone metabolism in human cells: Cytokinins are taken up and interconverted in HeLa cell culture

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19

AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019

Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials

Barriers to Psychologists Seeking Mental Health Care

Dissolution Challenges Associated with the Surface pH of Drug Particles: Integration into Mechanistic Oral Absorption Modeling

Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults

Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial

Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial

Serum AZD7442 (tixagevimab–cilgavimab) concentrations and in vitro IC50 values predict SARS‐CoV‐2 neutralising antibody titres

Intramuscular AZD7442

529. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Phase 3 Study

1354. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of COVID-19: 15-Month Final Analysis of the PROVENT Phase 3 Study

1353. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of COVID-19: Final Analysis of the STORM CHASER Phase 3 Study

LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults

Assessing multimodal emotion recognition in multiple sclerosis with a clinically accessible measure

Serum AZD7442 (tixagevimab–cilgavimab) concentrations and in vitro IC 50 values predict SARS‐CoV‐2 neutralising antibody titres

Serum AZD7442 (tixagevimab-cilgavimab) concentrations and in vitroIC50 values predict SARS-CoV-2 neutralising antibody titres

1924. Outpatient Treatment With the SARS-CoV-2–Neutralizing Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) for Preventing COVID-19 Hospitalizations in the Phase 3 TACKLE Trial

Suchergebnisse filtern